Ophthotech announced it failed to meet its endpoint of mean change in visual acuity at the 12-month mark for a Phase 3 clinical trial of Fovista compared to Eyla or Avastin.
AVEO Pharmaceuticals, Staar Surgical, Vericel, PDL BioPharma, Natural Alternatives top the NASDAQ biotech stock list.
FibroGen saw its stock skyrocket following a disclosure of positive data from a phase 2 trial of its idiopathic pulmonary fibrosis (IPF) drug pamrevlumab.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
Following the failure of AstraZeneca for its immuno-oncology lung cancer treatment clinical trial, analysts at Braclays indicate what’s tech in the I/O space is now at the top.
Theralase achieves exploratory endpoint of efficacy for anti-cancer technology.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the completion of the first site initiation visit at the Dent Neurological Institute (“Dent”) for its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (“STAR-3”). Site initiation visits are generally the final step before patient enrollment.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3).
“IRB approval is an essential step in initiating patient enrollment in our
Thanks to new data from its Phase 3 Trial Clovis Oncology saw a 50 percent increase in its stock on Monday (June 19)
By Jocelyn Aspa
VMware (NYSE:VMW) has announced that it has been named a Leader in the 2017 Gartner Magic Quadrant for Enterprise Mobility Management (EMM) for the seventh year in a row.
As quoted in the press release:
VMware AirWatch® placed the highest in ability to execute for the fifth year in a row and
Oncolytics Biotech revealed the publication of new data from two new studies, set to be presented at the upcoming American Society of Clinical Oncology meeting.